November 9, 2026

Company: KYORIN Pharmaceutical Co., Ltd.
Representative: Yutaka Ogihara
Representative Director, President and CEO
(Security Code: 4569, TSE Prime.)
Contact: Shota Kikuchi
Director, Corporate Planning
Telephone: 03-6374-9702

Notice Regarding Difference Between Financial Forecast and Actual Results for the Interim Period of FY2026 and Revision of Financial Forecasts for FY2026

KYORIN Pharmaceutical Co., Ltd. announced that the following differences between the financial forecast for the interim period of fiscal year ending March 31, 2027, which were announced on May 12, 2026, and the actual financial results announced today, and the revision of the consolidated financial forecasts for fiscal year ending March 31, 2027 based on the actual results as follows.

1. Difference between consolidated financial forecast and actual results for the interim period of the fiscal year ending March 31, 2027 (from April 1, 2026 to September 30, 2026)

	Net sales	Operating profit	Ordinary profit	Profit attributable to owners of parent	Net profit per share
	Million yen	Million yen	Million yen	Million yen	yen
Previously forecast (A)	57,800	−300	−100	0	0.00
Actual (B)	**57,489**	**306**	**689**	**−1,566**	**−27.26**
Change (B-A)	−311	+606	+789	−1,566	−27.26
Percentage change (%)	−0.5	—	—	—	—
(Ref.) Actual Results for the Interim Period of the Fiscal Year Ending March 31, 2026	58,731	1,363	1,582	1,494	26.01

2. Difference between financial forecast and actual results for the interim period of the fiscal year ending March 31, 2027 (from April 1, 2026 to September 30, 2026)

	Net sales	Operating profit	Ordinary profit	Net profit	Net profit per share
	Million yen	Million yen	Million yen	Million yen	yen
Previously forecast (A)	50,000	500	900	500	8.70
Actual (B)	**49,604**	**1,417**	**1,949**	**789**	**13.74**
Change (B-A)	−396	+917	+1,049	+289	+5.04
Percentage change (%)	−0.8	+183.5	+116.6	+58.0	+58.0
(Ref.) Actual Results for the Interim Period of the Fiscal Year Ending March 31, 2026	51,652	2,045	2,439	2,109	36.71

3. Revision of consolidated financial forecast for the fiscal year ending March 31, 2027 (from April 1, 2026 to March 31, 2027)

	Net sales	Operating profit	Ordinary profit	Profit attributable to owners of parent	Net profit per share
	Million yen	Million yen	Million yen	Million yen	yen
Previously forecast (A)	121,800	2,000	2,300	1,500	26.11
Revised forecasts (B)	**121,800**	**−4,900**	**−4,600**	**−5,100**	**−88.74**
Change (B-A)	—	−6,900	−6,900	−6,600	−114.85
Percentage change (%)	—	—	—	—	—
(Ref.) Actual Results for the Fiscal Year Ending March 31, 2026	126,257	3,567	4,031	3,448	60.03

4. Revision of financial forecast for the fiscal year ending March 31, 2027 (from April 1, 2026 to March 31, 2027)

	Net sales	Operating profit	Ordinary profit	Net profit	Net profit per share
	Million yen	Million yen	Million yen	Million yen	Yen
Previously forecast (A)	105,400	2,600	3,300	2,200	38.29
Revised forecasts (B)	**105,400**	**−4,300**	**−3,600**	**−2,900**	**−50.45**
Change (B-A)	—	−6,900	−6,900	−5,100	−88.74
Percentage change (%)	—	—	—	—	—
(Ref.) Actual Results for the Fiscal Year Ending March 31, 2026	110,934	4,285	5,048	4,183	72.82

5. Reasons for the differences and revision

(Differences between interim financial forecasts and actual results)

Net sales for the current interim period of the fiscal year fell short of the previously announced forecast, as sales of Lasvic and Mucodyne fell short of expectations, among other factors. Operating profit and ordinary profit exceeded the previously announced forecasts, primarily driven by unspent selling, general and administrative expenses. Profit attributable to owners of parent fell short of the previously announced forecast, due to the recording of an extraordinary loss, including a loss on the transfer of the generic drug business.

(Revision of full-year financial forecasts)

For the full-year financial forecasts, we have revised the forecasts for operating profit and ordinary profit to reflect the upfront payment associated with the license agreement for Paridiprubart (EB05), a therapeutic agent for Acute Respiratory Distress Syndrome (ARDS), with Edesa Biotech, Inc., announced today, as well as the impact of upfront payments for acquiring licensed products that, while not yet finalized as of today, are deemed highly certain based on progress in negotiations with the counterparty. In addition, the forecast for profit attributable to owners of parent reflects the aforementioned factors as well as the loss on the transfer of the generic drug business recorded as an extraordinary loss in the interim period.

**Explanations about the appropriate use of the business forecasts and other noteworthy points. These forecast performance figures are based on information currently available to the Company and may include uncertain factors or risk that affect our future performance. Accordingly, actual business results may materially differ from the forecasted figures due to various factors in the future.*

**This document is for reference purposes only. In case of any discrepancy, the Japanese version shall prevail.*